Form 4 for RCUS Arcus Biosciences, Inc.
Accepted 2023-06-16 00:00:00 ET · period of report 2023-06-15 · accession 0001209191-23-038141 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-06-16 | 2023-06-15 | RCUS | KANEKO YASUNORI | Dir | A - Grant | $0.00 | +6,800 | 6,800 | New | $0 |
| D | 2023-06-16 | 2023-06-15 | RCUS | KANEKO YASUNORI | Dir | A - Grant | $0.00 | +19.5K | 19.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-06-15 | A | A | 6,800 | $0.00 | 6,800 | D | — | — | (F1) Represents the grant of restricted stock units that vest in full on the earlier of June 15, 2024 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-06-15 | A | A | 19,500 | $0.00 | 19,500 | D | $19.60 · — to 2033-06-14 | 19,500 Common Stock | (F3) The option will vest in full on the earlier of June 15, 2024 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control. |